- Company plans to highlight preclinical
proof-of-concept data for EO-3021 in an oral presentation at
the New Drugs on the Horizon special session
NEW
YORK, March 14, 2023 /PRNewswire/ -- Elevation
Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company
focused on the discovery and development of selective cancer
therapies to treat patients across a range of solid tumors with
significant unmet medical needs, today announced that preclinical
proof-of-concept data for EO-3021 will be highlighted in an oral
presentation at the New Drugs on the Horizon special session at the
American Association for Cancer Research (AACR) Annual Meeting
2023, being held April 14-19, 2023 in
Orlando, Florida. A poster
highlighting the preclinical data for EO-3021, a potential
best-in-class antibody-drug conjugate (ADC) designed to target
Claudin 18.2, will also be presented at the conference.
"The oral presentation at this year's AACR New Drugs on the
Horizon session is an exciting opportunity for Elevation Oncology
to showcase preclinical data for EO-3021 as a potential
best-in-class ADC targeting solid tumors expressing Claudin 18.2.,"
said David Dornan, Chief Scientific
Officer of Elevation Oncology. "In addition, we look forward to
presenting the preclinical data in more detail in a poster session
at AACR and remain on track to initiate a U.S. Phase 1 clinical
trial evaluating EO-3021 during the second half of 2023."
Elevation Oncology will also present two posters on NRG1
fusions, including updated data from the Phase 2 CRESTONE study
evaluating seribantumab in patients with solid tumors harboring
NRG1 fusions. Elevation Oncology announced in January 2023 that it has paused enrollment in the
Phase 2 CRESTONE study and further investment in seribantumab,
pending entering a partnership.
Details of presentations at AACR 2023 are as follows:
Title: EO-3021: An antibody drug conjugate targeting
CLDN18.2 expressing cancers
Presentation: Oral Presentation by David Dornan, Chief Scientific Officer,
Elevation Oncology
Session Type: Drug Development Track: Special Session - New
Drugs on the Horizon Session: Part 3
Data and Time: Monday, April 17,
2023, 10:15AM-11:45AM ET
Title: Therapeutic potential of EO-3021/SYSA1801, a
Claudin18.2 antibody-drug conjugate, for the treatment of
CLDN18.2-expressing cancers
Authors: Mo Dan, et al.
Session Type: Poster Presentation
Session: Experimental and Molecular Therapeutics - Growth
Factor Receptors as Therapeutic Targets
Abstract Number: 6300
Data and Time: Wednesday, April 19,
2023, 9:00AM-12:00PM ET
Title: Identification of NRG1 fusions in patients with
solid tumors: Analysis from a real-world community oncology
network
Authors: Emma G. Sturgill, et
al.
Session Type: Poster Presentation
Session: Clinical Research Excluding Trials - Analyses Using
Clinical and Genomic Databases
Abstract Number: 921
Data and Time: Sunday, April 16,
2023, 1:30PM-5:00PM ET
Title: CRESTONE: A Phase 2 study of seribantumab in adult
patients with neuregulin-1 (NRG1) fusion positive locally advanced
or metastatic solid tumors
Authors: Tejas Patil, et
al.
Session Type: Poster Presentation
Session: Phase II Clinical Trials 2
Abstract Number: CT229
Data and Time: Tuesday, April 18,
2023, 9:00AM-12:30PM ET
About Elevation Oncology, Inc.
Elevation Oncology is an innovative oncology company focused on
the discovery and development of selective cancer therapies to
treat patients across a range of solid tumors with significant
unmet medical needs. We are rethinking drug development by seeking
out innovative, selective cancer therapies that can be matched to a
patient's unique tumor characteristics. Our lead candidate,
EO-3021, is a potential best-in-class antibody drug conjugate (ADC)
designed to target Claudin 18.2, a clinically validated molecular
target. EO-3021 selectively delivers a cytotoxic payload directly
to cancer cells expressing Claudin 18.2. We are working to rapidly
advance EO-3021 into the clinic in the US across a range of solid
tumor indications, as well as exploring other opportunities through
new or existing partnerships and business development opportunities
to expand our novel oncology pipeline. For more information, visit
www.ElevationOncology.com.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995, including, but not
limited to, anticipated preclinical and clinical development
activities, expected timing of announcements of clinical results,
potential benefits of Elevation Oncology's product candidates and
the ability of Elevation Oncology's product candidates to treat
their targeted indications. All statements other than statements of
historical fact are statements that could be deemed forward-looking
statements. These forward-looking statements may be accompanied by
such words as "aim," "anticipate," "believe," "could," "estimate,"
"expect," "forecast," "goal," "intend," "may," "might," "plan,"
"potential," "possible," "will," "would," and other words and terms
of similar meaning. Although Elevation Oncology believes that the
expectations reflected in such forward-looking statements are
reasonable, Elevation Oncology cannot guarantee future events,
results, actions, levels of activity, performance or achievements,
and the timing and results of biotechnology development and
potential regulatory approval is inherently uncertain.
Forward-looking statements are subject to risks and uncertainties
that may cause Elevation Oncology's actual activities or results to
differ significantly from those expressed in any forward-looking
statement, including risks and uncertainties related to Elevation
Oncology's ability to advance its product candidates, the timing
and results of preclinical studies and clinical trials, approvals
and commercialization of product candidates, the receipt and timing
of potential regulatory designations, the impact of the COVID-19
pandemic on Elevation Oncology's business, Elevation Oncology's
ability to fund development activities and achieve development
goals, Elevation Oncology's ability to protect intellectual
property, Elevation Oncology's ability to establish and maintain
collaborations with third parties and other risks and uncertainties
described under the heading "Risk Factors" in documents Elevation
Oncology files from time to time with the Securities and Exchange
Commission. These forward-looking statements speak only as of the
date of this press release, and Elevation Oncology undertakes no
obligation to revise or update any forward-looking statements to
reflect events or circumstances after the date hereof.
Elevation Oncology Investor and Media Contact
Candice Masse, 978-879-7273
Senior Director, Corporate Communications & Investor
Relations
cmasse@elevationoncology.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/elevation-oncology-to-present-at-the-american-association-of-cancer-research-aacr-annual-meeting-2023-301771911.html
SOURCE Elevation Oncology